Product Information
PHENTERMINE 37.5 MG TABLET is a generic product labeled by Elite Laboratories, Inc., priced at $0.0727 per EA under NDC 64850081001. Its NADAC has been published 169 times since Jul 12, 2023.
FDA first approved this application on May 30, 1997. Its Orange Book therapeutic-equivalence code is AA.
Strength
37.5 mg/1
Manufacturer
Elite Laboratories, Inc.NDC
64850081001
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PHENTERMINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA040190FDA Approved
5/30/1997
TE Code
AA
On Market Since
5/1/2014
Pharmacological Classes
Price Statistics
The NADAC for PHENTERMINE 37.5 MG TABLET has been published 169 times since Jul 12, 2023, and over the history we have for it it has declined 19.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0727 per EA |
|---|---|
| All-time high | $0.1040 (Mar 13, 2024) |
| All-time low | $0.0494 (Nov 20, 2024) |
| 52-week high | $0.0727 |
| 52-week low | $0.0670 |
| Median price | $0.0727 |
| Average price | $0.0737 |
| Largest weekly change | +51.9% (Jun 19, 2024) |
| Weeks tracked | 169 |
| Tracking since | Jul 12, 2023 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Elite Laboratories, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Phentermine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sympathomimetic Amine Anorectic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PHENTERMINE 37.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PHENTERMINE 37.5 MG TABLET, manufactured by Elite Laboratories, Inc., is $0.0727 per EA (NDC 64850081001), effective Sep 30, 2026.
How has the price of PHENTERMINE 37.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for PHENTERMINE 37.5 MG TABLET has declined 19.7%. It has been tracked across 169 weekly CMS publications since Jul 12, 2023.
What are the highest and lowest recorded NADAC prices for PHENTERMINE 37.5 MG TABLET?
Since Jul 12, 2023, the NADAC for PHENTERMINE 37.5 MG TABLET has ranged from a low of $0.0494 (Nov 20, 2024) to a high of $0.1040 (Mar 13, 2024), with a median of $0.0727 per EA.
Are there cheaper alternatives to PHENTERMINE 37.5 MG TABLET?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PHENTERMINE 37.5 MG TABLET, is $0.0697 per EA — about 4% below PHENTERMINE 37.5 MG TABLET.
Who manufactures PHENTERMINE 37.5 MG TABLET?
PHENTERMINE 37.5 MG TABLET (NDC 64850081001) is labeled by Elite Laboratories, Inc., and CMS classifies it as a generic product.